| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
118,760,000 |
| Market
Cap: |
290.96(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.54 - $3.06 |
|
| Level
I Sector: |
Basic Materials |
| Level
II Sector: |
Chemicals |
| Level
III Sector: |
Synthetics |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 10.1 |
| Insider 3/6 Months : 10.7 |
|
| Guru Rank Number : 670 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Heron Therapeutics is a commercial-stage biotechnology company focused on developing treatments for acute care and oncology patients. Co.'s main product, SUSTOL is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide combination chemotherapy regimens. Co.'s other products include: CINVANTI, which is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy; and ZYNRELEF, which is indicated in adults for soft tissue or periarticular instillation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
310,000 |
2,796,744 |
2,796,744 |
| Total Buy Value |
$0 |
$287,814 |
$3,694,653 |
$3,694,653 |
| Total People Bought |
0 |
3 |
4 |
4 |
| Total Buy Transactions |
0 |
4 |
5 |
5 |
| Total Shares Sold |
0 |
0 |
0 |
1,504 |
| Total Sell Value |
$0 |
$0 |
$0 |
$7,154 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Quart Barry D |
Chief Executive Officer |
• • – |
2021-01-13 |
4 |
D |
$18.16 |
$17,488 |
D/D |
(963) |
91,909 |
|
- |
|
| Quart Barry D |
Chief Executive Officer |
• • – |
2021-01-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,646 |
92,872 |
|
- |
|
| Szekeres David Leslie |
EVP, Chief Operating Officer |
• – – |
2021-01-13 |
4 |
D |
$18.16 |
$7,682 |
D/D |
(423) |
827 |
|
- |
|
| Szekeres David Leslie |
EVP, Chief Operating Officer |
• – – |
2021-01-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
1,250 |
|
- |
|
| Manhard Kimberly |
EVP, Drug Development |
• • – |
2021-01-13 |
4 |
D |
$18.16 |
$7,863 |
D/D |
(433) |
817 |
|
- |
|
| Manhard Kimberly |
EVP, Drug Development |
• • – |
2021-01-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
1,250 |
|
- |
|
| Poyhonen John |
President & CCO |
• – – |
2021-01-13 |
4 |
D |
$18.16 |
$7,863 |
D/D |
(433) |
19,597 |
|
- |
|
| Poyhonen John |
President & CCO |
• – – |
2021-01-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
20,030 |
|
- |
|
| Szekeres David Leslie |
EVP, Chief Operating Officer |
• – – |
2021-01-08 |
4 |
AS |
$19.66 |
$70,219 |
D/D |
(3,571) |
0 |
|
-29% |
|
| Manhard Kimberly |
EVP, Drug Development |
• • – |
2020-12-22 |
4 |
AS |
$20.00 |
$200,000 |
D/D |
(10,000) |
0 |
|
-17% |
|
| Manhard Kimberly |
EVP, Drug Development |
• • – |
2020-12-22 |
4 |
OE |
$13.00 |
$130,000 |
D/D |
10,000 |
10,000 |
|
- |
|
| Davis Stephen |
Director |
– • – |
2020-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
3,000 |
|
- |
|
| Christian Waage |
Director |
– • – |
2020-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
4,400 |
|
- |
|
| Johnson Craig A |
Director |
– • – |
2020-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
3,840 |
|
- |
|
| Poyhonen John |
President & CCO |
• – – |
2020-10-30 |
4 |
A |
$11.65 |
$7,423 |
D/D |
637 |
18,780 |
|
- |
|
| Szekeres David Leslie |
EVP, Chief Operating OfficerOf |
• – – |
2020-10-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,571 |
|
14% |
|
| Peraza Lisa |
VP, Chief Accounting OfficerOf |
• – – |
2020-10-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,259 |
|
14% |
|
| Manhard Kimberly |
Executive VP, Drug Development |
• • – |
2020-05-01 |
4 |
AS |
$13.97 |
$16,176 |
D/D |
(1,158) |
0 |
|
6% |
|
| Quart Barry D |
Chief Executive Officer |
• • – |
2020-04-30 |
4 |
A |
$12.12 |
$14,036 |
D/D |
1,158 |
89,226 |
|
- |
|
| Manhard Kimberly |
Executive VP, Drug Development |
• • – |
2020-04-30 |
4 |
A |
$12.12 |
$14,036 |
D/D |
1,158 |
1,158 |
|
- |
|
| Manhard Kimberly |
Executive VP, Drug Development |
• • – |
2019-11-29 |
4 |
AS |
$26.00 |
$624,000 |
D/D |
(24,000) |
0 |
|
- |
|
| Manhard Kimberly |
Executive VP, Drug Development |
• • – |
2019-11-29 |
4 |
OE |
$13.00 |
$312,000 |
D/D |
24,000 |
24,000 |
|
- |
|
| Tang Kevin C |
Director |
– • – |
2019-10-04 |
4 |
B |
$17.50 |
$4,999,995 |
I/I |
285,714 |
5,799,810 |
2.1 |
- |
|
| Poyhonen John |
EVP, Chief Commercial Officer |
• • – |
2019-10-03 |
4 |
B |
$17.50 |
$90,003 |
D/D |
5,143 |
18,143 |
2.81 |
- |
|
| Quart Barry D |
Chief Executive Officer |
• • – |
2019-10-03 |
4 |
B |
$17.50 |
$79,993 |
D/D |
4,571 |
94,652 |
2.81 |
- |
|
502 Records found
|
|
Page 7 of 21 |
|
|
0.10 (3.92%) 
